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Objectives
FMF is an autosomal recessive disease, caused by muta-
tions in the MEFV gene, encoding the pyrin protein
associated with the interleukin-1b related inflammation
cascade. In FMF overproduction of IL-1b and uncon-
trolled TNF-a release has been documented. These
cytokines mediate activation of endothelial cells causing
sustained inflammatory response and endothelial cell
dysfunction[1]. Vascular injuries are frequently seen in
FMF patients although the exact mechanisms are not
well understood. We design this study to determine the
role of endothelial biomarkers in pathogenesis of vascu-
lopathy in FMF.
Methods
The study cohort included 50 FMF patients with vascular
involvement (VI, mean age 39.7±12, male/female 23/27) -
group 1, and 52 FMF patients without VI (31.6±11,
32/20) - group 2. A total of 50 healthy subjects between
16-67 years of age were enrolled as controls. All patients
diagnosed in accordance with Tel-Hashomer criteria. VI
was determined by physical examination, lab tests and
instrumental modalities (ECG, Doppler echocardiogra-
phy, CT-scan and MRI). The patients group with VI
included 30 FMF patients with coronary heart disease (2
of them with myocardial infarction), 14 with pulmonary
hypertension, 2 with stroke, 1 with poliarteritis nodosa,
1 with Henoch-Schonlein purpura, 1 with livedoid vascu-
lopathy and 1 with Raynaud’s phenomenon. Laboratory
tests, including leucocyte count, erythrocyte sedimenta-
tion rate, fibrinogen, C-reactive protein, serum amyloid-
A, nitric oxide and endothelin-1 were carried out on all
patients in attack free period. CRP was determined by
immunoturbidimetric method and SAA by ELISA. Serum
NO and plasma ET-1 levels were measured by Griess
reaction and enzyme immunoassay, respectively. Normal
values of NO and ET-1 in our laboratory were <20μmol/L
and 7.2±4pg/ml, respectively.
Results
Fibrinogen and leucocyte count were normal in patient
groups (mean±SD, group 1 vs group 2) 4.46±1.1g/L vs
3.57±1 and 8.5±2.4 (x109)g/L vs 7.4±1.6, whereas ESR
was increased 30.3±18.7 mm/h vs 19±12.6. Mean CRP
and SAA were significantly higher in group 1 than in
group 2 (21.06±16.8 mg/L vs 12,5±12.1, t=2.94, p<0.01;
30.56±63.3 mg/L vs 10.47±32,79, t=2,0013, P<0,05,
respectively). The mean level of NO was lower in group
2 than in controls (3.12±0.75μmol/l vs 8.79±2.72 μmol/l,
t=14.2, p<0.0001) and in group 1 than in group 2
(2.79±0.7 μmol/l vs 3.12±0.75 μmol/l, t=2.3, p<0.05),
though it was within normal ranges. Although there
were no correlations between NO, fibrinogen, leuco-
cytes, ESR and SAA in both patients group, there were
negative correlations between NO and CRP (r=-0.338,
p=0,016, group 1; r=-0,398, p=0,003, group 2). There
was a significant difference in ET-1 levels between the
controls and the patient group 2 (7.8.±1.99 pg/ml vs
16.2±7.32 pg/ml, t=7.97, p<0.0001) and between the
patient group 2 and 1 (16.2±7.32 pg/ml vs 23.13±14.8
pg/ml, t=2.98, p<0.05). Also ET-1 levels showed positive
correlations with CRP in patient groups (r=0,585,
p=0,000, group 1 and r=0,285, p=0,041, group 2), and
with SAA in group 1 (r=0,459, p=0,001). No correlations
were found between ET-1, fibrinogen, leucocytes and
ESR.
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Conclusions
Endothelial biomarkers were found abnormal in patients
with FMF. We have shown that levels of NO in FMF
patients were normal, but lower compared with healthy
controls. Expression of NO is induced drastically by mul-
tiple stimuli- interferon-a, tumor necrosis factor-a and
IL-1b that induce iNOS (inducible nitric oxide synthase)
expression in macrophages, leucocytes and vascular
endothelial cells [1]. NO inhibits the biochemical effect
of ET-1, however, ET-1 induces iNOS expression in
endothelial cells. Impaired NO production may contri-
bute to the pathogenesis of vascular injury in FMF.
We have revealed an increased ET-1 level in the patients
with FMF associated vascular disease. We have also
demonstrated that there were significant correlations
between ET-1 levels and inflammatory markers, such as
CRP and SAA, in the patients with FMF associated vascu-
lar disease. We conclude that continuous low-grade
inflammation in FMF may cause vascular injury and
endothelial dysfunction that may lead to vasoconstriction
and ischemic complications in FMF patients with the
development of cardiovascular, pulmonary, neurological
and other vascular events. Last but not least, endothelin-1
may have a role in the pathogenesis of FMF associated
vascular disease.
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